

Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences

SARASOTA, FL, UNITED STATES, October 2, 2026 /EINPresswire.com/ --

[Lakewood-Amedex Biotherapeutics, Inc.](https://www.lakewoodamedex.com/) (NASDAQ: LABT, the "Company"), a clinical-stage biotechnology company advancing a novel class of potent, fast-acting, broad-spectrum antimicrobials for infectious diseases called the Bisphosphocin® class, today announced that CEO Kelvin Cooper, Ph.D., will participate in three upcoming industry conferences.

Lakewood-Amedex Biotherapeutics Inc. is a [B2i Digital Featured Company](https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1). See the company's in-depth profile at: <https://b2idigital.com/lakewood-amedex-biotherapeutics-inc-1>

Dr. Cooper is scheduled to attend the Maxim Growth Summit on October 14, 2026, in New York City. He will also attend and present at the ThinkEquity Conference on October 15, 2026, in New York City. Later in the month, Dr. Cooper will present a poster on Nu-3 preclinical data at IDWeek on October 22, 2026, in Washington, D.C.

Details are as follows:

Event: Maxim Growth Summit

Date: October 13-14, 2026

Location: Hard Rock Hotel, New York City



Lakewood-Amedex CEO Kelvin Cooper, Ph.D., will participate in three October conferences, highlighting the Company's Nu-3 antimicrobial development program.

Event: ThinkEquity Conference
Date: October 15, 2026
Location: The Mandarin Oriental Hotel,
New York City
Presentation: Nu-3 – A Novel, Broad
Spectrum Antimicrobial Compound
with High In- Vitro Activity Against
Resistant Pathogens for the Treatment
of Infected Diabetic Foot Ulcers.
Presentation Time: 3:30 pm

Event: IDWeek
Date: October 21-24, 2026
Location: Walter E. Washington
Convention Center, Washington, D.C.
(Hybrid Format Available)

The conferences provide opportunities
for Lakewood-Amedex to engage with
members of the investment,
biotechnology, and infectious disease communities and highlight the Company's ongoing
development programs Bisphosphocin® antimicrobial technology.

About Lakewood-Amedex Biotherapeutics, Inc.

Lakewood-Amedex Biotherapeutics, Inc. (NASDAQ: LABT) is a clinical-stage biotechnology
Company developing a novel class of fast-acting, broad-spectrum antimicrobials – the
Bisphosphocin® class - to treat infectious diseases and reduce the threat posed by antibiotic-
resistant bacterial strains, including MRSA, VRE, and others. For more information, please visit
<https://lakewoodamedex.com>.

Contacts:

Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com

Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com

The graphic features a teal background with a blurred image of laboratory glassware. In the top left, the 'b2i digital' logo is present. In the top right, the text 'FEATURED COMPANY' is displayed. The center of the graphic is dominated by the 'Lakewood Amedex' logo, which includes a circular cluster of colorful dots to the left of the company name. Below the company name, the word 'BIOTHERAPEUTICS' is written in a smaller font. At the bottom of the graphic, a blue banner contains the text 'NASDAQ: LABT'.

NASDAQ: LABT

Lakewood-Amedex will showcase Nu-3 and its
Bisphosphocin® antimicrobial technology at the
Maxim Growth Summit, ThinkEquity Conference and
IDWeek.

Michelle Katsel
(201) 790-3390
mkatsel@tiberend.com

Additional Contact

David Shapiro
B2i Digital, Inc.
+1 212-579-4844
david@b2idigital.com
Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[TikTok](#)

[X](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/946937979>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.